Syndax Pharmaceuticals, Inc. (SNDX) Balance Sheet

NASDAQ: SNDXAssets, liabilities, debt and equity over 10 years.

SNDX balance sheet, 2025

December 31, 2025 · U.S. dollars

$529.7M assets = $465.1M liabilities + $64.6M equity

What it owns$529.7MCash & ST investments: $413.7M (78.1%)Cash & ST investments$413.7M · 78%Receivables: $70.3M (13.3%)Receivables$70.3M · 13%Inventory: $32.8M (6.2%)Inventory $32.8MOther current: $11.3M (2.1%)PP&E: $1.5M (0.3%)Other non-current: $102,000 (0.0%)=How it is financed$529.7MCurrent liabilities: $120.1M (22.7%)Current liabilities$120.1M · 23%Long-term debt: $343.9M (64.9%)Long-term debt$343.9M · 65%Other LT liabilities: $1.1M (0.2%)Shareholders’ equity: $64.6M (12.2%)Shareholders’ equity$64.6M · 12%

Both columns are drawn to the same scale: what SNDX owns equals what it owes plus shareholders’ equity. Hover a block for its value.

SNDX financial health

Current ratio4.40
Comfortable · current assets cover current liabilities 4.40×
Debt / equity5.36
High leverage · $5.36 of debt for each $1 of equity
Equity / assets12.2%
Thin equity · of assets funded by shareholders
Cash / debt119.4%
Cash covers debt · cash & short-term investments vs total debt
Goodwill & intangibles0.0%
Mostly tangible · of total assets

Descriptive bands, not a rating. Fiscal 2025.

SNDX balance sheet trends, 2016–2025

Syndax Pharmaceuticals, Inc. balance sheet trends
MetricTrendThenLatestChange
Total assets$109.0M2016$529.7M2025+19.2%/yr
Total liabilities$24.9M2016$465.1M2025+38.5%/yr
Shareholders’ equity$84.1M2016$64.6M2025−2.9%/yr
Cash & short-term investments$105.3M2016$413.7M2025+16.4%/yr
Total debt$6.4M2016$346.5M2025+55.9%/yr
Net cash (debt)$98.9M2016$67.2M2025−$31.7M
Working capital$98.1M2016$408.0M2025+$309.8M
Book value per share$4.972017$0.752025−21.1%/yr
Current ratio10.4720164.402025−6.07
Debt / equity0.0820165.362025+5.29
Shares outstanding21.0M201786.6M2025+19.4%/yr

Change is the average annual growth (CAGR) or the difference between the first and latest year.

SNDX assets

Cash & ST investmentsReceivablesInventoryOther currentPP&EGoodwill & intangiblesLT investmentsOther non-current

SNDX liabilities and equity

Current liabilitiesLong-term debtOther long-term liabilitiesEquity

SNDX debt vs cash

Total debtCash & ST investmentsNet cash (debt)

Debt includes short- and long-term borrowings and, where reported, lease obligations.

SNDX balance sheet

Syndax Pharmaceuticals, Inc. annual balance sheet
2025202420232022202120202019201820172016
Assets
Cash & short-term investments$413.7M$582.9M$577.6M$484.4M$446.8M$293.1M$59.8M$80.9M$133.2M$105.3M
Cash & equivalents$134.9M$154.1M$295.4M$74.4M$222.0M$115.2M$24.6M$33.8M$35.2M$23.8M
Short-term investments$278.8M$428.8M$282.2M$410.0M$224.9M$177.8M$35.2M$47.1M$94.8M$81.5M
Receivables$70.3M$13.9M$1.2M$4.1M$429,000$175,000$116,000$253,000$377,000$306,000
Inventory$32.8M$366,000$2.0M−$4.3M$7.7M$5.3M$1.7M$1.1M−$1.4M$2.4M
Other current assets$11.3M$5.9M$63,000$5.6M$0$341,000$763,000$1.1M$1.3M$464,000
Total current assets$528.1M$603.1M$580.9M$489.8M$448.4M$298.9M$62.3M$83.3M$133.4M$108.5M
Property, plant & equipment (net)$1.5M$2.0M$1.5M$1.1M$1.3M$482,000$997,000$373,000$267,000$260,000
Goodwill & intangible assets$0$0$0$0$0$0$0$0$0$0
Long-term investments$0$119.5M$29.8M$5.5M$0$0$0$0$3.2M$0
Other non-current assets$102,000$217,000$680,000$922,000$0$1.3M$197,000$219,000$231,000$243,000
Total assets$529.7M$724.8M$612.9M$497.2M$449.7M$300.6M$63.5M$83.9M$137.2M$109.0M
Liabilities
Accounts payable$16.6M$11.6M$10.0M$4.3M$5.7M$3.5M$6.2M$1.4M$2.2M$2.4M
Short-term debt$472,000$12.6M$1.0M$439,000$362,000$2.6M$478,000$13.0M$11.8M$6.4M
Deferred revenue——$39.0M—$12.8M$1.5M$1.5M$1.5M$1.6M$1.2M
Total current liabilities$120.1M$103.5M$58.1M$29.1M$20.7M$18.9M$18.4M$16.1M$15.8M$10.4M
Long-term debt$343.9M$331.6M$0$0$19.9M$17.8M$0$0$0$0
Lease obligations$1.5M$2.1M$1.6M$1.2M$1.1M$417,000$897,000———
Other long-term liabilities$1.1M$1.6M$588,000$722,000$711,336$11.7M$13.6M$14.8M$17.1M$14.5M
Total liabilities$465.1M$436.7M$58.7M$29.8M$41.3M$48.4M$31.9M$30.9M$32.9M$24.9M
Shareholders' equity
Common stock & paid-in capital$9,000$9,000$8,000$7,000$6,000$5,000$3,000$2,000$2,000$2,000
Retained earnings (deficit)−$1.51B−$1.22B−$902.4M−$693.0M−$543.7M−$568.6M−$495.5M−$439.4M−$366.1M−$305.3M
Accumulated other comprehensive income$452,000$163,000$218,000−$806,000$45,000−$4,000−$310,000−$25,000−$143,000$56,000
Total shareholders' equity$64.6M$288.1M$554.2M$467.4M$408.4M$252.2M$31.6M$53.0M$104.3M$84.1M
Key figures
Total debt$346.5M$345.7M$1.6M$1.2M$21.0M$20.5M$897,000$13.0M$11.8M$6.4M
Net cash (debt)$67.2M$237.2M$575.9M$483.2M$425.9M$272.5M$58.9M$67.9M$121.4M$98.9M
Working capital$408.0M$499.5M$522.8M$460.7M$427.7M$280.0M$44.0M$67.2M$117.6M$98.1M
Tangible book value$64.6M$288.1M$554.2M$467.4M$408.4M$252.2M$31.6M$53.0M$104.3M$84.1M
Book value per share$0.75$3.37$7.88$7.69$7.84$6.11$1.04$2.09$4.97—
Shares outstanding86.6M85.6M70.4M60.8M52.1M41.3M30.5M25.4M21.0M—
Current ratio4.405.8210.0016.8521.6815.843.395.188.4510.47
Quick ratio4.035.769.9616.8121.6215.543.265.048.4610.19
Debt / equity5.361.200.000.000.050.080.030.250.110.08
Equity / assets12.2%39.8%90.4%94.0%90.8%83.9%49.7%63.2%76.0%77.2%

Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed February 26, 2026); data from EODHD.

SNDX financial position

At the end of fiscal 2025 (December 31, 2025), Syndax Pharmaceuticals had total assets of $529.7 million (down 26.9% from a year earlier), total liabilities of $465.1 million and shareholders' equity of $64.6 million. It held $413.7 million in cash and short-term investments against $346.5 million of debt, a net cash position of $67.2 million. Its current ratio was 4.40. In the latest quarter (ended June 30, 2026) total assets were $703.7 million and equity $15.1 million.

Related: SNDX income statement, SNDX cash flow statement, SNDX key metrics. See the SNDX stock overview for the latest quote and news.

SNDX balance sheet FAQ

What are Syndax Pharmaceuticals's total assets?

Syndax Pharmaceuticals reported total assets of $529.7 million at the end of fiscal 2025 (December 31, 2025), compared with $724.8 million a year earlier.

How much debt does Syndax Pharmaceuticals have?

Syndax Pharmaceuticals had $346.5 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 5.36.

How much cash does Syndax Pharmaceuticals have?

Syndax Pharmaceuticals held $413.7 million in cash and short-term investments at the end of fiscal 2025; with $346.5 million of debt that is net cash of $67.2 million.

What is Syndax Pharmaceuticals's book value?

Syndax Pharmaceuticals's shareholders' equity (book value) was $64.6 million at the end of fiscal 2025, or $0.75 per share.

What is Syndax Pharmaceuticals's current ratio?

Syndax Pharmaceuticals had current assets of $528.1 million and current liabilities of $120.1 million, a current ratio of 4.40 (it can cover its short-term obligations).

Biotechnology: balance sheet